August 22, 2013

The National Advertising Review Board determined that certain claims made by Matrixx Initiatives for its Zicam Cold Remedy products would not reasonably be understood to mean that use of the products prevents colds.

April 5, 2013

The National Advertising Division on Friday recommended that Matrixx Initiatives discontinue advertising claims that suggest its homeopathic Zicam Cold Remedy products prevent users from catching a cold.

March 12, 2013

Public relations and digital marketing firm Robin Leedy and Associates has added three new clients, the firm said Tuesday.

October 29, 2012

ProPhase Labs on Monday again rejected an acquisition proposal from Matrixx Initiatives. Matrixx's latest offer was to acquire ProPhase for $1.60 per share in cash, up from a prior $1.40 per share proposal.

October 9, 2012

Matrixx Initiatives on Tuesday announced its second overture to ProPhase Labs with an increased acquisition offer of $1.60 per share.

September 17, 2012

ProPhase Labs on Monday announced that it rejected an unsolicited, nonbinding proposal from Matrixx Initiatives to acquire the company for $1.40 per share in cash, subject to further due diligence by Matrixx.

June 8, 2011

With former Wyeth executive Dennis O’Donnell at the helm, Matrixx Initiatives is making a headquarter transition from Phoenix to here in New Jersey, according to a story published in the Arizona Republic earlier this week.

February 18, 2011

NEW YORK — The second half of the 2010-2011 cough-cold-flu season actually may realize greater sales of symptom relievers than last year, judging from the four weeks ended Dec. 26. According to Matrixx president and CEO Bill Hemelt, sales of remedies were on the rise in those four weeks. Hemelt noted that the total cough-cold category was 5% higher than the same period last year and growing. 


January 21, 2011

Matrixx Initiatives on Friday provided a summary of the ongoing "go-shop" process initiated by the company after Wonder Holdings proposed a merger agreement. The “go-shop” process is scheduled to run through Jan. 22.

January 21, 2011

Cough-cold supplier Matrixx on Thursday credited tough comparisons against the prior season’s high pre-season inventory purchases by retailers due to the publicity of the H1N1 flu outbreak for the lower level of sales for the quarter ended Dec. 31, 2010.

December 14, 2010

Matrixx Initiatives on Tuesday announced that it has entered into a definitive merger agreement to be acquired by affiliates of private equity firm H.I.G. Capital.

October 25, 2010

Matrixx Initiatives on Monday reported a decline of 17% in net sales to $21.3 million...

September 26, 2010

The pharmaceutical industry earlier this month weighed in on the case “Matrixx Initiatives vs. James...

August 29, 2010

Industry lobbyists last week weighed in on a Ninth Circuit ruling that allowed for a...

August 22, 2010

There are three factors that will help shape the upcoming cough-cold season: supply chain, illness...

June 6, 2010

Matrixx Initiatives recently introduced a new line of Zicam products—Cold Remedy Plus—a multi-ingredient formulation that...

May 18, 2010

Matrixx Initiatives on Wednesday named William Barba VP finance and accounting and treasurer effective May 6....

March 16, 2010

Matrixx Initiatives recently introduced a new line of Zicam products — Cold Remedy Plus, a...